Update shared on25 Sep 2025
Fair value Increased 3.48%Analysts raised Mirum Pharmaceuticals’ price target from $78.27 to $81.00, citing surging Livmarli sales, strong Q2 results, a robust and expanding rare disease pipeline, and continued commercial execution.
Analyst Commentary
- Bullish analysts meaningfully increased Livmarli sales forecasts following Mirum's strong Q2 earnings beat and upwardly revised 2025 guidance.
- Anticipation of potentially registrational volixibat data in primary sclerosing cholangitis (Q2 2026) and primary biliary cholangitis is viewed as a significant near-term pipeline growth driver.
- Mirum is seen as unique in rare disease biotech for being cash flow positive, maintaining a high-growth commercial business, and having a diverse, credible pipeline of growth opportunities.
- Continued strong launch momentum for Livmarli further validates the company’s commercial execution and growth trajectory.
- Broader positive sentiment towards small- and mid-cap biotech due to a lengthening investor time horizon is leading to higher price targets across the sector.
What's in the News
- Completed enrollment in Phase 2b VISTAS study of volixibat for cholestatic pruritus in primary sclerosing cholangitis; topline results expected in Q2 2026.
- Volixibat also being evaluated in VANTAGE Phase 2b study for primary biliary cholangitis, with enrollment completion and topline results expected in 2026 and H1 2027, respectively.
- Raised 2025 revenue guidance to $490 million–$510 million.
- Dropped from multiple Russell indexes, including Microcap Growth, 3000E Growth, and Microcap Indexes.
Valuation Changes
Summary of Valuation Changes for Mirum Pharmaceuticals
- The Consensus Analyst Price Target has risen slightly from $78.27 to $81.00.
- The Net Profit Margin for Mirum Pharmaceuticals has risen from 12.86% to 14.15%.
- The Future P/E for Mirum Pharmaceuticals has fallen slightly from 53.17x to 50.57x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.